David Zhang | Vice President of Biometrics at MyoKardia

David Zhang is Vice President of Biometrics and Digital Health at MyoKardia, a biotech company dedicated to pioneering precision medicine for treatment of serious and neglected rare cardiovascular diseases. 

David has two decades of industry experience spanning from pharma, device to diagnostics product development. Prior to MyoKardia, he was Senior Director at Roche Sequencing Solutions where he had built the biometrics function from ground up and led the group to support the launch of circulating tumor DNA assay, Avenio®, to detect and monitor somatic mutations powered by the NGS technology.

David spent 13 years at Genentech with increasing responsibilities leading Biostatistics and Strategic Innovation groups. His contribution on the design and analysis of the single pivotal trial (RAVE) led to the launch of the only FDA approved therapy rituximab to treat Anca-associated Vasculitis (AAV), a severe and life threatening rare autoimmune disease. As Head of Strategic Partnerships, David led the creation of collaboration framework with external innovators to transform drug development at Genentech. David also produced and managed an Advisory Board model by bringing together 50 top internal leaders and leading innovation experts across industries from banking to oil and gas. This effort resulted in the creation of a global network of 100 leaders across Roche/Genentech to transform the drug development process by including the right subject matter advisors on the right projects internally and externally.

As part of his role of Innovation Challenge Leader, David successfully launched an innovative tool to gather external physician intelligence on trial design and feasibility in over 30 teams, resulting a saving of time and money while obtaining much broader inputs. He also led a cross-functional team focused on building an Open Innovation platform, which enabled the organization to systematically access innovations from external communities. To recognize is contribution in this area, he received the Excellence in Collaborative Innovation Award from NineSigma.

David spent his formative years in the industry at Eli Lilly and Abbott Laboratories. He received Ph.D. in biostatistics with minor in genetics from UCLA School of Public Health and completed post-doctoral research investigating familial psychiatric disorders at Columbia University. He also received an Executive MBA in finance from Indiana University Kelley School of Business.